Predict ADME parameters from molecular structure, combine in vitro P-CAB proton inhibition data, build PBPK-PD model to simulate intragastric pH curves, realize early human PK/PD assessment at preclinical stage.
B²O Pharma is an innovative pharmaceutical R&D enterprise focusing on AI-driven clinical pharmacology and quantitative pharmacology, dedicated to advancing model-informed drug development.